Ada Henrike Braun

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi Lysophosphatidic acid, a disintegrin and metalloprotease-17 and heparin-binding epidermal growth factor-like growth factor in ovarian cancer: the first word, not the last
    Ada H Braun
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Clin Cancer Res 11:4639-43. 2005
  2. ncbi The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan
    Ada Henrike Braun
    Department of Internal Medicine Cancer Research, West German Cancer Center, Essen, Germany
    Anticancer Drugs 16:1099-108. 2005

Collaborators

Detail Information

Publications2

  1. ncbi Lysophosphatidic acid, a disintegrin and metalloprotease-17 and heparin-binding epidermal growth factor-like growth factor in ovarian cancer: the first word, not the last
    Ada H Braun
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Clin Cancer Res 11:4639-43. 2005
  2. ncbi The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan
    Ada Henrike Braun
    Department of Internal Medicine Cancer Research, West German Cancer Center, Essen, Germany
    Anticancer Drugs 16:1099-108. 2005
    ..This study delineates mechanisms that may contribute to the synergism observed between irinotecan and EGFR inhibitors...